Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and raf kinase inhibition constitutes a putative therapeutic target

Neuroendocrinology

Volumn 85, Issue 1, 2007, Pages 45-53

  Karhoff, Dorothee ^a   Sauer, Susanne ^a   Schrader, Jörg ^a   Arnold, Rudolf ^a   Fendrich, Volker ^a   Bartsch, Detlef K ^a   Hörsch, Dieter ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Apoptosis; Extracellular signal regulated kinase; Neuroendocrine tumors; Proliferation; Protein kinase B; Raf kinase; Small G proteins

Indexed keywords

B RAF KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; RAF PROTEIN; RAP1 PROTEIN; SORAFENIB; TRANSCRIPTION FACTOR ELK 1;

APOPTOSIS; ARTICLE; CARCINOID; CELL GROWTH; CELL LINE; CONTROLLED STUDY; DIGESTIVE SYSTEM; DRUG INHIBITION; DRUG TARGETING; ENDOCRINE CELL; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; GASTRINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULINOMA; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BENZENESULFONATES; DIGESTIVE SYSTEM NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDINES; RAF KINASES; RAP1 GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES;

EID: 34047254705     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100508     Document Type: Article

References (30)

1. Rindi G, Capella C, Solcia E: Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic tumors. J Mol Med 1998;76:413-420.
2. Mignon M: Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000;62(suppl 1):51-58.
3. Solcia E, Klöppel G, Sobin LH (eds): Histological Typing of Endocrine Tumours. Berlin, Springer, 2000.
4. Fave GD, Corleto VD: Oncogenes, growth factors, receptor expression and proliferation markers in digestive neuroendocrine tumours. A critical reappraisal. Ann Oncol 2001;12(suppl 2):S13-S17.
5. Lubomierski N, Kersting M, Bert T, Muench K, Wulbrand U, Schuermann M, Bartsch D, Simon B: Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors. Cancer Res 2001;61:5905-5910.
6. Arnold R, Simon B, Wied M: Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 2000;62(suppl 1):84-91.
7. Oberg K: Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther 2003;3:863-877.
8. Schnirer II, Yao JC, Ajani JA: Carcinoid - a comprehensive review. Acta Oncol 2003;42:672-692.
9. Calender A: Molecular genetics of neuroendocrine tumors. Digestion 2000;62(suppl 1):3-18.
10. Corleto VD, Delle FG, Jensen RT: Molecular insights into gastrointestinal neuroendocrine tumours: importance and recent advances. Dig Liver Dis 2002;34:668-680.
11. Gilbert JA, Lloyd RV, Matthew MA: Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors. N Engl J Med 2005;353:209-210 (letter).
12. Hagemann C, Rapp UR: Isotype-specific functions of Raf kinases. Exp Cell Res 1999;253:34-46.
13. Kolch W: Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000;351:289-305.
14. Bos JL, de Rooij J, Reedquist KA: Rap1 signalling: adhering to new models. Nat Rev Mol Cell Biol 2001;2:369-377.
15. Ishida D, Kometani K, Yang H, Kakugawa K, Masuda K, Iwai K, Suzuki M, Itohara S, Nakahata T, Hiai H, Kawamoto H, Hattori M, Minato N: Myeloproliferative stem cell disorder by deregulated Rap-1 activation in SPA-1-deficient mice. Cancer Cell 2003;4:55-65.
16. Yajnik V, Paulding C, Sordella R, McClatchey AI, Saito M, Wahrer DC, Reynolds P, Bell DW, Lake R, van den Heuvel S, Settleman J, Haber DA: DOCK-4, a GTPase activator is disrupted during tumorigenesis. Cell 2003;112:673-684.
17. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997-7000.
18. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA: Mutations in the human BRAF gene in human cancer. Nature 2002;417:949-954.
19. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K, Takenoshita S: BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003;22:6455-6457.
20. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M: BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003;22:4578-4580.
21. O'Neill E, Kolch W: Conferring specificity on the ubiquitous Raf/MEK signalling pathway. Br J Cancer 2004;90:283-288.
22. Tannapfel A, Vomschloss S, Karhoff D, Markwarth A, Hengge UR, Wittekind C, Arnold R, Hörsch D: BRAF Gene mutations are rare events in gastroenteropancratic neuroendocrine tumors. Am J Clin Pathol 2005;123:256-260.
23. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
24. Lankat-Buttgereit B, Hörsch D, Barth P, Arnold R, Blocker S, Göke R: Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. Digestion 2005;71:131-140.
25. Trümper J, Ross D, Jahr H, Brendel MD, Göke R, Hörsch D: The Rap/B-Raf signaling module is activated by glucose and glucagonlike peptide-1 in human islet cells. Diabetologia 2005;48:1534-1540.
26. Trümper A, Trümper K, Trusheim H, Arnold R, Göke B, Hörsch D: Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol Endocrinol 2001;15:1559-1570.
27. Jin S, Zhou Y, Guo W, Field J: PAK1-dependent phosphorylation of RAF-1 regulates its mitochondrial localization, phosphorylation of BAD, and Bcl-2 association. J Biol Chem 2005;280:24698-24705.
28. Cornelis S, Bruynooghe Y, Van Loo G, Saelens X, Vandenabeele P, Beyaert R: Apoptosis of hematopoietic cells induced by growth factor withdrawal is associated with caspase-9 mediated cleavage of Raf-1. Oncogene 2005;24:1552-1562.
29. Rapp UR, Rennefahrt U, Troppmair J: Bcl-2 proteins: master switches at the intersection of death signaling and the survival control by Raf kinases. Biochim Biophys Acta 2004;1644:149-158.
30. Van Gompel JJ, Kunnimalaiyaan M, Holen K, Chen H: ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther 2005;4:910-917.